Please enable JavaScript.
Coggle requires JavaScript to display documents.
Top lessons learned from the article " A mandate for innovation in…
Top lessons learned from the article " A mandate for innovation in Pharma Manufacturing "
Current State of Majority of Pharma Companies.
Inefficient
Low Productivity.
Low Asset Productivity.
Poor Asset Design.
Poor Engineering.
Costly.
Inefficient.
No Innovation
Low Uptake of Modern Process Design Principles.
Low Uptake of Control & Measurement Technologies.
Low Uptake of Knowledge Management Systems.
Low uptake of Knowledge Management Systems.
Low Manufacturing Innovation.
Excess Capacity.
Low Supplier Collaboration.
Poor Quality Assurance.
Focused on cost reduction of labor and Procurement.
Other Traditional Manufacturing Industries
Automotive
Automation and Robotics.
Faster Changeover of Tools.
Market Demand Meet.
Just In Time Parts Delivery.
Outsourcing of Components.
Open to New Innovations.
Steel Industry
Transition to Small Scale Production.
Production Tied to Demand.
Energy Efficient.
Open to New Innovations.
Future Pharma Models, Based on Industries that Innovated.
The Intel Model.
Achievements.
Fast production.
Fast pipeline from Development to Manufacturing.
Fast Product to Market.
Low Cost.
High level of Operational Excellence.
Manufacturing Efficiency.
Speed and Agile Process.
Advanced Product design.
Advanced Manufacturing Technology.
Fast Product Changeover.
Quick Ramp-up of Chip Production.
Investment.
New Manufacturing Technologies.
New Product Design.
18 month Product cycle.
Less Power consumption.
New application for Chips.
Less expensive to product.
New Innovations.
Strategy.
Design for Manufacturing
.
Helps Resolve Issues Earlier in the Design Cycle.
Easier to Manufacture.
Better Quality.
Copy Production Plants Exactly
.
Aid Ramp-up of Production.
Multiply Site manufacturing.
Consistency in product.
Lessons for Pharma from Intel Model.
Concentrate on core Products.
Become Highly Automated.
Achieve Six Sigma performance Levels.
Source Fast and Precise Equipment.
Quality Built In to the Process.
Increase Training.
Product Cost effective Products.
Quick Ramp-up of Drug Production.
Drug Development to Market Time faster.
The Nucor Model
.
Achievements.
Lower Setup Costs.
Small Scale Production.
Plants Situated beside customers.
Smaller Batch Sizes.
Manufacturing Efficiency.
Quality Embedded in the Process Stages.
Flexible Production.
Use of Cheaper Recycled Materials.
Low Running Costs.
Just In Time Production.
Investment.
Electric Arc Furnaces
Recycling Technologies.
New Innovations.
Continuous Casting "Castrip".
Manufacturing Management System.
Strategy.
Collaborating with other manufacturers.
Small Scale Plants.
Lower Running Costs.
Sourcing Lower Cost Raw Materials in Developing Countries.
Lessons For Pharma from Nucor Model.
Tighter Integration with Suppliers.
Streamlining of Processes.
Install Fast in place cleaning systems.
Install Embedded Automated Quality testing.
Standardized Low Cost Packaging on Product.
Homogenized labeling on Product.
Low Amounts of Work In Progress.
Train and Hire Highly Skilled Personnel.
Central Manufacturing Management System,
Rapid Repair to Minimize Down Time.
The Disney Model.
Achievements.
Media Business.
Films.
Games.
Complementary Entertainment Business
Hotels.
Product Franchise
Theme Parks.
Merchandising
Investment.
Brand Identity.
Growing Complementary Operations.
Strategy.
Value Chain Partnerships.
Offsetting Film Production costs.
Film Sequels.
Film Spinoffs
.
Games.
Theme Parks.
Toys.
Merchandises
Data Management Systems.
Lessons For Pharma from Disney Model.
Data Management.
Customer.
Automated Pharmacy with Patient Data.
Customers Receive Drug Product information.
Send Real Time Product Usage Data for Management of illness.
Create Customer Support call centers.
Counterfeit Preventative applications.
Collect Data for Regulatory process.
Create an Information Management group.
Smart Technologies.
Apps.
Bar-codes.
Embedded Chips.
Databases with Patient and Drug information.
Model Implementation implications for the Pharma Industry.
Model Efficiencies will boost value for the Pharma Shareholders.
Different Models for Different Markets.
Solving challenges.
Partnerships.
Licensing of Product.
Identify Pharma Innovation Implementation Owners.
Cross Functional Team
Leadership Type.
Changing Old Thinking.
Fostering New Ideas.
Having a Clear future Picture.
Pushing the innovation forward.
See a competitive reason to Innovate.
Models foster fresh thinking to leaders to achieve "Plantopia".
Pharma New Strategy Drivers.
Business Requirements.
More Price Transparency.
Less Productive R&D pipeline.
Smaller Batches.
Higher Quality Expectations
Shorter Exclusivity Time Periods.
Innovation
.
Operational Excellence.
Global Forces.
New Emerging Markets.
Different Regulatory Standards Worldwide.
Shorter Periods of Drug Exclusivity.
High Quality Expectations.
Changing Customer Needs.
Price Reductions.
Drug Efficacy.
Immunization Programs in Developing Countries.
More Customers World wide.
Technology Developments.
Cell Design.
Single Use Technology - Disposable Reactors.
Controller Environment Modules.
Process Automation.
Electronic Batch Records.
Quick product change Over.
Continuous Batch.
Control Limits.
PAT Analytic.
Quality By Design.
Value-Chain Inefficiencies.
Market Requirements.
Nuanced Partnerships.
New Global Supplies.
Counterfeiting of Drugs.
Competition from emerging markets.
China.
India.
